Results 31 to 40 of about 8,863 (150)

Nail disease in psoriatic arthritis. Data from the Russian Psoriatic Arthritis Registry

Научно-практическая ревматология, 2021
Objective of the study – to compare, in real clinical practice, according to the data of the Russian Psoriatic Arthritis Registry, characteristics of two groups of psoriatic arthritis (PsA) patients: with and without nail psoriasis.Material and methods ...
E. E. Gubar, Y. L. Korsakova, E. Yu. Loginova, T. V. Korotaeva, E. A. Vasilenko, A. A. Vasilenko, N. A. Kuznetsova, I. M. Patkikeeva, E. L. Nasonov   +8 more
doaj   +1 more source

Short‐Term Response to Biologic Therapy in Psoriatic Arthritis Is Not Influenced by Disease Duration at Initiation of Therapy

Arthritis Care &Research, EarlyView.
Objective We aimed to determine whether the short‐term response to biologics in biologic‐naive psoriatic arthritis (PsA) is better in patients initiating biologic treatment early in the disease course. Methods Patients with PsA who started on biologic therapy from the year 2000 to 2025 were included for analysis.
Sung Min Cho, Shangyi Gao, Daniel Pereira, Richard J. Cook, Dafna D. Gladman   +4 more
wiley   +1 more source

Nail Psoriasis in a Child Observed Under Ultraviolet Dermoscopy Treated by a Topical Biological Agent Cream: A Case Report

International Journal of Dermatology and Venerology, 2021
. Introduction:. Nail psoriasis is a type of psoriasis involving nail lesions characterized by pitting, onycholysis, longitudinal ridges, and subungual hyperkeratosis.
Run-Yan Gao, Sushmita Pradhan, Yu-Ping Ran   +2 more
doaj   +1 more source

Supramolecular Degraders: An Emerging Paradigm in Targeted Protein Degradation

Advanced Science, EarlyView.
Dynamic supramolecular assembly reshapes targeted protein degradation by coordinating modular degrader construction, delivery, functional integration, and intracellular assembly or activation across proteasomal, endosomal–lysosomal, and autophagy–lysosomal pathways.
Kongjun Liu, Xue Yuan, Yan Zhou, Rui Yuan, Shaocheng Xie, Yong Chen, Peiyi Wang, Jianmei Gao, Qihai Gong   +8 more
wiley   +1 more source

Efficacy of Biologics Targeting Tumour Necrosis Factor-alpha, Interleukin-17 -12/23, -23 and Small Molecules Targeting JAK and PDE4 in the Treatment of Nail Psoriasis: A Network Meta-analysis

Acta Dermato-Venereologica, 2020
The comparative efficacy of registered anti-psoriatic biologics and small molecules in treating nail symptoms has not been systematically evaluated. The aim of this study was to perform a network meta-analysis to determine the efficacy of biologics and ...
Júlia Szebényi, Noémi Gede, Péter Hegyi, Zsolt Szakács, Margit Solymár, Bálint Erőss, András Garami, Kornélia Farkas, Dezső Csupor, Rolland Gyulai   +9 more
doaj   +1 more source

Combination Therapy in Participants With Active Psoriatic Arthritis Using Subcutaneous Guselkumab and Golimumab: Week 24 Results From a Phase 2a, Multicenter, Randomized, Double‐Blind, Proof‐of‐Concept Study

Arthritis &Rheumatology, EarlyView.
Objective To assess guselkumab + golimumab combination therapy versus guselkumab monotherapy in participants with active psoriatic arthritis (PsA) and inadequate response to tumor necrosis factor inhibitors (TNFi‐IR). Methods Adults with active TNFi‐IR PsA (three or more tender/swollen joints) were randomized (2:1) to subcutaneous guselkumab (100 mg) +
Jose U. Scher, Iain B. McInnes, Enrique R. Soriano, Joseph F. Merola, Paul Bird, Vinod Chandran, Edaire Cheng, Elena Reynoso, Warner Chen, Maoji Li, Lianne S. Gensler, Philip J. Mease, Christopher T. Ritchlin   +12 more
wiley   +1 more source

From Interferon Signature to the Clinical Landscape: Type I Interferonopathies

Arthritis &Rheumatology, EarlyView.
Objective TypeI interferonopathies are heterogeneous diseases driven by dysregulated type I interferon (IFN‐I) signaling. Diagnosis is challenging due to clinical/molecular variability and the need for IFN‐I quantification. The aim of this study was to characterize the clinical, immunologic, genetic, molecular profiles of patients with suspected ...
Ismail Yaz, Seza Ozen, Hacer Neslihan Bildik, Canberk Ipsir, Dilara Unal, Saliha Esenboga, Begum Cicek, Mehmet Emin Seker, Fatima Aerts‐Kaya, Seher Sener, Mehmet Orhan Erkan, Hanife Avci, Deniz Cagdas, Ilhan Tezcan   +13 more
wiley   +1 more source

Deucravacitinib in Active Psoriatic Arthritis: Efficacy and Safety Up to 52 Weeks From the Randomized, Double‐Blind, Phase 3 POETYK PsA‐2 Trial

Arthritis &Rheumatology, EarlyView.
Objective To assess the efficacy and safety of deucravacitinib, an oral, selective tyrosine kinase 2 inhibitor, in patients with psoriatic arthritis (PsA) who were naive to biologic disease‐modifying antirheumatic drugs or received tumor necrosis factor inhibitors. Methods In the 52‐week, double‐blind, placebo‐controlled, phase 3 Program for Evaluation
Philip J. Mease, Vinod Chandran, April W. Armstrong, Ricardo Blanco, Alexis Ogdie, Evan L. Siegel, Alice B. Gottlieb, Xiaofeng Zeng, Diamant Thaçi, Mitsumasa Kishimoto, Hendrik Schulze‐Koops, Alan Kivitz, Eva Dokoupilová, Akimichi Morita, Eric M. Ruderman, Michael Plewinski, Kejia Wang, Caroline Sardinas, Eleni Vritzali, John Vaile, Atul Deodhar   +20 more
wiley   +1 more source

NAPSI utilization as an evaluation method of nail psoriasis in patients using acitretin Utilização do NAPSI como instrumento de avaliação na psoríase ungueal em pacientes com uso da acitretina

Anais Brasileiros de Dermatologia, 2012
BACKGROUND: assessment instruments of nail psoriasis have been published in literature as means to standardize the previous subjective assessments of authors.
Maira Mitsue Mukai, Isabela Fleischfresser Poffo, Betina Werner, Fabiane Mulinari Brenner, José Hermênio Cavalcante Lima Filho   +4 more
doaj   +1 more source

Multi‐omics–driven precision medicine

iMeta, EarlyView.
Multi‐omics‐driven precision medicine (MODPM) provides a multiscale, continuously learnable framework that integrates genomics, epigenomics, transcriptomics, proteomics, metabolomics, microbiome profiles, and clinical data. Powered by artificial intelligence and foundation models, MODPM enables cross‐modal representation learning, contextual modeling ...
Huibo Li, Zhe Zhao, Yifan Zhang, Yao Ma, Gaofei Hu, Min Zeng, Zhanqun Yang, Zixuan Zhao, Xin Zhou, Wei Hu, Yuxuan Sun, Meng Su, Jun Li, Matthew Whiteman, Wei Fu, Chao Zhong, Lemin Zheng, Long Chen, Hairong Lv, Rongsheng Zhao, Yi Zhun Zhu   +20 more
wiley   +1 more source